Optimization Of AAV Production For High-Yielding And Scalable GMP Processes

By Mathieu Porte, BioProduction R&D Manager, Claire Wartel, Director of Quality and Compliance, Bhargavi Kondragunta, Director of Internal R&D & Product Development, Catalent Cell & Gene Therapy

The cell and gene therapy market continues to grow rapidly due to increasing numbers of approvals for commercial use, molecules reaching late-stage clinical studies, and early-stage candidates. This growth is fueling significant demand for critical raw materials and driving suppliers to develop strategies and products that enable this expansion.

Viral vectors currently constitute the main delivery vehicles for both gene therapies and genetically modified (adoptive) cell therapies. The gene therapy clinical pipeline is evolving worldwide, with dramatic increases in the number of clinical trials, many of which involve products that leverage viral vector delivery. The demand for AAV production is growing at a more rapid rate than that for LV production because AAV-based gene therapies are administered at higher doses than the quantity of LV vectors required to genetically modify cells for adoptive cell therapies.

Learn how by leveraging a standardized, scalable platform approach for viral vector manufacturing, including the transient transfection step, timelines can be accelerated to bring next-generation therapies to market.